Navigation Links
BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
Date:1/30/2009

Toronto Stock Exchange Symbol: MS

EDMONTON, Jan. 30 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced results from MINDSET-01, an exploratory phase II clinical trial evaluating dirucotide in patients with relapsing-remitting MS. The lead clinical development program for dirucotide is for secondary progressive MS where it is being evaluated in two ongoing phase III trials in the United States, Canada and Europe, with results from the Canadian and European MAESTRO-01 trial expected in the second half of 2009.

The results of the MINDSET-01 study showed that dirucotide did not meet its primary endpoint, annualized relapse rate or associated secondary MRI endpoints. Dirucotide did meet certain secondary endpoints related to the progression of the disease, including mean change from baseline in the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) score. The EDSS is a method of quantifying disability in MS, while the MSFC evaluates additional functional parameters. Measuring changes in EDSS and MSFC are primary and secondary outcomes in the ongoing phase III secondary progressive MS trials.

The data also showed that dirucotide was generally well tolerated. The most common side effects reported were redness and burning sensation at the injection site. No patients withdrew due to adverse events.

BioMS and its partner Eli Lilly & Company (Lilly) will continue to analyze the results of this exploratory phase II trial. Under the terms of the licensing agreement with Lilly, no milestone payment was associated with this trial.

"We are encouraged that dirucotide has demonstrated an effect on certain clinical measures of disease progression, this time in the earlier form of the disease," said Kevin Giese, President and CEO of BioMS Medical. "Dirucotide was developed as a potential treatment f
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioMS Medical recognized at Scrip Awards 2008
2. BioMS Medical Announces Third Quarter 2008 Results
3. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
4. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
5. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
6. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
7. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
8. BioMS Medical to present at UBS Global Life Sciences Conference
9. BioMS Medicals lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA
10. BioMS Medical announces its intention to renew a normal course issuer bid
11. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... FORT LAUDERDALE, Fla. , Sept. 17, 2014 ... signed an agreement to form a Special Purpose Vehicle in ... based Jatropha centric agro energy company. The SPV shall ... U.S. registered entity with AFAI as majority shareholder. The SPV ... Africa , particularly Ethiopia . ...
(Date:9/17/2014)... RXi Pharmaceuticals Corporation (NASDAQ: ... developing and commercializing innovative therapies addressing major unmet ... has been granted a patent by the United ... delivery system for delivering its "original" RNAi compounds ... treatment of diseases with an inflammatory component. Potential ...
(Date:9/17/2014)... CA (PRWEB) September 17, 2014 Escape Alert, ... for pets which will alert owners if their pet has ... GPS from an implanted microchip in the pet’s body. This ... microchips for pets have been around for many years, they ... are not able to track a pet’s location or alert the ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 The ... committed to lowering the barriers to innovation in ... the appointment of Carmen Nitsche as Executive Director ... to expand its global reach. , Carmen joins ... Vice President, Corporate Development. At Accelrys, she managed ...
Breaking Biology Technology:AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 2AFAI Signs Joint Venture Agreement With Jatro Greentech Inc. 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 2RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 4Implantable Microchip for Pets with GPS Tracking - Patent Filed by Escape Alert, LLC. 2Implantable Microchip for Pets with GPS Tracking - Patent Filed by Escape Alert, LLC. 3Pistoia Alliance Expands Business Development with Appointment of Carmen Nitsche 2
... photonics and renewable energy will be the focus of ... to 14, 2009 at McMaster University in Hamilton, Ontario, ... in conjunction with the event. , The 4th Nano ... the 14th Canadian Semiconductor Technology Conference (CSTC2009) will bring ...
... UC Riverside have made an accidental discovery in ... information in computers can be transported or stored. ... electrons possess that makes them behave like tiny ... of spin-based semiconductor technology such as ultrahigh-speed computers. ...
... programs give sponsors easy-to-use tools to store, mine and ... transfer knowledge base to ensure enrollment success, NEWTON, ... technology leader, announced the release of a new,product, "Center ... in-house recruitment capabilities for clinical,trial sponsors. The goal is ...
Cached Biology Technology:Joint nanotechnology forum to focus on electronics, photonics, renewable energy 2Discovery by UC Riverside physicists could enable development of faster computers 2Discovery by UC Riverside physicists could enable development of faster computers 3TCN e-Systems Offers Trial Sponsors Solutions for Creating In-House Center of Excellence in Patient Recruitment 2TCN e-Systems Offers Trial Sponsors Solutions for Creating In-House Center of Excellence in Patient Recruitment 3TCN e-Systems Offers Trial Sponsors Solutions for Creating In-House Center of Excellence in Patient Recruitment 4
(Date:9/17/2014)... learned a great deal about complex social behavior by ... something to teach too. , With their unusually large ... parrots live in a complex social environment---not merely in ... or ants, but in a dynamic setting of alliances ... intelligent mammals: dolphins, whales, primates, and social carnivores, like ...
(Date:9/16/2014)... Environmental Health at the Mailman School of Public Health ... asthma and prenatal exposure to two phthalates used in ... in the journal Environmental Health Perspectives . ... higher levels of the chemicals, butylbenzyl phthalate (BBzP) and ... percent increase in risk of developing asthma between age ...
(Date:9/16/2014)... CLEVELAND, Ohio (September 17, 2014)The North American Menopause ... for the comprehensive care of midlife womenon everything ... feature, "The North American Menopause Society Recommendations for ... today in the Society,s journal Menopause . ... recommendations for the care of midlife women freely ...
Breaking Biology News(10 mins):Being social: Learning from the behavior of birds 2Phthalates heighten risk for childhood asthma 2Phthalates heighten risk for childhood asthma 3
... A team of scientists from the University Hospitals of ... bowel diseases have low bone mass and poor bone architecture ... at increased risk of fracture. Inflammatory bowel disease ... inflammation of the bowel. Two of the most common disorders ...
... new study presented today at the World Congress on ... a commonly used injectible contraceptive, is associated with higher ... in combination with estrogens. Depot medroxyprogesterone acetate ... birth control drug which is injected every 3 months. ...
... muscle tissue experiences trauma or disease, such as ... as "satellite cells" respond to repair and regenerate ... neuromuscular diseases, such as muscular dystrophy, which affect ... researchers have used time-lapse photography to document satellite ...
Cached Biology News:Caught on tape: Muscle stem cells captured on video by MU researcher 2
Anti-ADAM-12 (Meltrin Alpha); amino terminal region; rabbit host...
Mouse monoclonal [3G8] to MDMA ( Abpromise for all tested applications)....
Fluorescein isothiocyanate (FITC) mouse anti-human IFN-alpha2 25 tests...
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
Biology Products: